Current stock page

Stock Analysis

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis

Bio-Rad Laboratories, Inc. (BIO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

BIO Stock Analysis Summary

Bio-Rad Laboratories, Inc. (BIO) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 80/100. Quality is the weakest current factor at 61/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data

BIO at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$370.17
AIQ Score73/100
Overall ViewBullish
Technical Analysis ConsensusSell
Market Cap$9.81B
P/E Ratio (TTM)9.39
Forward P/E—
EPS (Q3 FY2026)$17.13
Revenue (Q3 FY2026)$656.4M
Dividend Yield (TTM)0.00%
Beta0.73
Volume460.48K
52-week range$236.73-$396.23
RSI 1445.43
50-Day SMA$372.95
200-Day SMA$316.99
Analyst Price Target—
Next EarningsFeb 11, 2027
As of Nov 18, 2026 · Market close

BIOBio-Rad Laboratories, Inc.

Healthcare / Medical - Devices

Leader

Sector Leader

BullishEdge 10/10
$370.17+$11.98 (+3.34%)

Latest quote

  • Momentum
    79
  • Value
    80
  • Quality
    61
  • Risk resilience
    74
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

BIO Stock Analysis Summary

Bio-Rad Laboratories, Inc. (BIO) currently has an AIQ Score of 73/100, indicating a bullish setup. Value is the strongest factor at 80/100. Quality is the weakest current factor at 61/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, BIO has AIQ Score of 73/100 with Value base of 80/100 and fading Quality at 61/100. Wait for component alignment before adding exposure.

Healthcare · 3.34% stock move · BIO classified in Medical - Devices.

Current Evidence

BullishBIO is in a bullish AIQ regime; Value is the strongest visible factor at 80/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is BIO Bullish or Bearish Right Now?

BIO currently has a bullish overall setup. Value is the strongest factor at 80/100, while Quality is weakest at 61/100. The current evidence suggests a constructive setup.

Bull Case
  • - Momentum is constructive at 79/100.
  • - Risk Resilience is supportive at 74/100.
Bear Case
  • - Technical consensus has more sell votes than buy votes (26 vs 13).

Current Consensus

BIO's Technical Analysis Consensus is currently Sell, with 13 buy, 7 neutral, and 26 sell votes. BIO's 14-day RSI is 45.43, which places the stock in a neutral momentum range. BIO's beta is 0.73, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in BIO?

The largest recent change in BIO is Momentum moving down by 5.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
-2.0
Momentum
-5.0
Quality
+0.0
Risk
+2.0

What Would Change the BIO Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

BIO Decision Framework

Public evidence layers, setup checks, and risk context for Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis

Bio-Rad Laboratories, Inc. has an AIQ Score of 73/100 in a Bullish regime. Value is strongest at 80/100. Beta is 0.73, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextBIO is in a Bullish AIQ regime with score 73/100.
Signal ConflictThe primary conflict is that value leads at 80/100 while quality lags at 61/100.
Factor EvidenceMomentum 79/100 · Value 80/100 · Quality 61/100 · Risk 74/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 80/100.

TimingPass

Momentum is 79/100 and RSI (14) is 45.4.

Regime fitPass

BIO is in a Bullish regime at 73/100.

Risk controlPass

Risk factor is 74/100 with beta 0.73 and annual volatility 36.18%.

ConflictPass

Current conflict: value leads at 80/100 while quality lags at 61/100.

AIQ Score
73/100
Price
$370.17
Beta
0.73
RSI (14)
45.4

BIO Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

BIO Fundamentals

BIO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$656.4M
Net income
$458.6M
Free cash flow
$65.2M
View full BIO fundamental analysis

BIO Technical Analysis

BIO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
45.43
Price vs SMA-50
-1.77%
View full BIO technical analysis

BIO Stock Catalysts

Track BIO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 11, 2027
Analyst target
—
News items
4
View BIO earnings and stock catalysts

BIO Dividend Analysis

BIO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View BIO dividend history and analysis

BIO Financial Data

BIO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$656.4M
EPS
$17.13
Periods
8
View BIO financials

BIO Risk Analysis

BIO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.73
Risk score
74/100
1Y volatility
36.18%
View BIO risk analysis

BIO Stock News

BIO stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 18, 2026
Sentiment
—
Read BIO stock news

BIO vs Medical - Devices Peers

Current peer cohort: BIO · BRKR · CNMD · ESTA · GKOS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
BIO
Current stock
73/10080/10079/10074/1000.4736.18%Current
BRKR
Bruker Corporation
64/10053/10083/10044/1000.8959.79%BIO vs BRKR
CNMD
CONMED Corporation
71/10084/10074/10058/1000.4846.99%BIO vs CNMD
ESTA
Establishment Labs Holdings Inc.
48/10032/10058/10047/1000.3549.89%BIO vs ESTA
GKOS
Glaukos Corporation
65/10030/10090/10057/1001.8361.36%BIO vs GKOS
Pairwise Compare links: BRKR · CNMD · ESTA · GKOSBIO vs BRKRBIO vs CNMDBIO vs ESTABIO vs GKOSCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 18, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a BIO stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for BIO: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 19, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
9.39
As of Nov 18, 2026
Revenue growth
0.52%
Gross margin
51.26%
Current debt / equity
0.18
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$656.4M
Quarter net income
$458.6M
Quarter free cash flow
$65.2M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
45.43
MACD
2.06

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
74/100
Beta
0.73
Annual volatility
36.18%
Max drawdown
-27.24%

BIO Stock FAQ

What is BIO stock price today?

Bio-Rad Laboratories, Inc.'s current stock price is $370.17. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is BIO bullish or bearish right now?

BIO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is BIO's market cap?

BIO's market cap is $9.81B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is BIO's current P/E ratio?

BIO's current P/E ratio is 9.39 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is BIO's RSI?

BIO's 14-day RSI is 45.43 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is BIO above its 50-day and 200-day moving averages?

BIO is -1.77% from its 50-day SMA and 15.57% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is BIO's next earnings date?

BIO's next earnings date is currently listed as Feb 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does BIO pay a dividend?

BIO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.